You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response.
Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
According to Myriad, the NOVA study shows that myChoice HRD can double the number of ovarian cancer patients who will respond to niraparib compared to other tests.